Trial Profile
Phase II, Open-Label, Study of CAELYX and Carboplatin Intermediate Platinum-Sensitive (6-12 Months Treatment-free Interval) Relapsed Epithelial Ovarian Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Carboplatin
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 14 Nov 2008 New trial record.